Novel NRXN1 Therapeutic Target in ADC for Small Cell Lung Cancer
Release Date: 24-Nov-2020
A super novel study focuses on carrying a research with respect to the apoptosis assay of NRXN1-targeted antibody drug conjugate at IC50 dose with the help of growth inhibition curves. According to the researchers who are oriented towards the research study, they identified and reported transmembrane proteins that were specifically overexpressed in case of small cell lung cancer and whereas were absent in the normal cell. Soon, this became the major focus area of the researchers i.e. cell adhesion molecule neurexin-1. The technique that was used to confirm the presence of the cell adhesion molecule neurexin-1 in the small cell lung cancer was cytometry.
For exaggerating the anti-tumor activity in the cell lines of small cell lung cancer, combination of primary anti-NRXN1 monoclonal antibody as well as secondary antibody drug conjugate was used. It was reported that the knockout of NRXNI in the cell lines of SHP77 resulted in no tumor activity of NRXN1 medicated antibody drug conjugate therapy. Therefore, it was concluded by the researchers that the targeting of NRXN1 could be observed as a novel therapeutic target for increasing the efficiency of antibody drug conjugate therapy for the treatment of the patients who are suffering from small cell lung cancer.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.